RECQL4 and glioma: Knockout of RECQL4 in LN18 and LN229 human glioma cells using the CRISPR/Cas9 editing, resulted in profound changes in the transcriptome, reduced glioma sphere formation capabilities and augmented vulnerability to TMZ [14].